Suzanne Trudel

Initial genome sequencing and analysis of multiple myeloma

Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats et al. · Nature · 2011 · 1.4K citations · Full text

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 988 citations · Full text

Hematological Malignancy, Disease Heterogeneity, Widespread Genetic Heterogeneity +7

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 772 citations

Hematological Malignancy, Medicine, Pathology +6

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 654 citations · Full text

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Craig B. Reeder, Donna Reece, Vishal Kukreti et al. · Leukemia · 2009 · 369 citations · Full text

Hematological Malignancy, Health Sciences, Medicine +8